The Beagle Trade

The commercial beagle trade is a regulated supply chain connecting a small number of purpose-bred breeding facilities to a global network of contract research organizations (CROs) and pharmaceutical companies. The dog is the cheapest component. The system around it is worth billions.

The Five Stages

A beagle bred for research flows through five stages:

1. 1.Breeding — Specialized colonies at [USDA Class A licensed](/wiki/usda-licensing) facilities produce purpose-bred dogs. Major breeders: [Marshall BioResources](/wiki/marshall-bioresources), [Ridglan Farms](/wiki/ridglan-farms) (closing 2026), [Envigo](/wiki/envigo) (closed 2022).
2. 2.Raising and conditioning — Dogs are grown to sale age (~4-6 months), vaccinated, health-screened, and acclimated to handling.
3. 3.Transport — Domestic ground vans or [international air freight](/wiki/transport-and-logistics). EU imports 1,763 dogs annually from outside the EU.^1
4. 4.Laboratory use — Regulatory toxicology, safety pharmacology, and related studies at [CROs](/wiki/contract-research-organizations) or in-house pharma labs.
5. 5.Post-use outcomes — Euthanasia and necropsy (~95%). Reuse in some cases (~39% in EU data). Adoption in rare cases under [beagle freedom laws](/wiki/beagle-freedom-laws).

The Breeders

The industry is extraordinarily concentrated:

• Marshall BioResources — the world's largest. ~23,000 dogs at North Rose, NY. Global operations in the US, UK, France, China, Italy, Japan. "Marshall Beagle" is a registered trademark and de facto industry standard.
• Ridglan Farms — the nation's second-largest. ~3,200 dogs in Blue Mounds, WI. Surrendering its license to sell dogs by July 2026 after 311 state violations.
• Envigo — operated ~5,000 dogs in Cumberland, VA. Shut down in 2022 after DOJ enforcement. $35 million fine — the largest Animal Welfare Act penalty in history.

With Envigo gone and Ridglan closing, Marshall approaches monopoly status in the US market.

The Buyers

Contract research organizations are the primary purchasers:

• Charles River Laboratories — ~$4 billion revenue. Also breeds its own research animals.
• Labcorp Drug Development (formerly Covance) — major preclinical testing operation
• Inotiv — acquired Envigo in 2021; the Cumberland shutdown devastated the company
• Altasciences — ~700 canines at one facility, 700+ safety studies annually

Nearly every major pharmaceutical company uses beagles through these intermediaries: Pfizer, Merck, J&J, AstraZeneca, Novartis, Roche, Eli Lilly, BMS, AbbVie, GSK. The CRO model keeps pharma companies at arm's length from the dogs.

The Money

• $1,100-$1,500 per dog — the purchase price (Envigo averaged ~$1,100; Ridglan charged ~$1,500)²
• $319,600 for a 90-day toxicology study — the standard OECD TG 409 protocol³
• $1,023,800 for a chronic oral toxicity study — longer-duration dog studies exceed $1 million
• The dog costs less than 0.2% of the study — it is the cheapest input in a multi-million-dollar regulatory process

The global preclinical CRO market exceeds $20 billion annually.⁴

The Numbers

All major jurisdictions show downward trends. But the decline reflects reductions in academic and teaching use — regulated product safety testing, the core of beagle demand, has remained stable or increased.⁵

Sources

1. 1.European Commission ALURES data, 2022. EU+Norway origin reporting shows 1,763 dogs from outside EU.
2. 2.U.S. DOJ statement on Envigo: ~$16M from ~15,000 dogs (2019-2022), ~$1.1k/dog average. Ridglan price from 2026 local journalism.
3. 3.U.S. EPA OCSPP cost estimates, inflation-adjusted to 2024.
4. 4.Corporate Players. Charles River Laboratories FY2024 revenue of $4.05 billion.
5. 5.Dominant Lab Dogs. Industry is now the dominant U.S. user of dogs (34,875 of 60,190 in 2017).